Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Leukaemias
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Leukaemias
    Annual Report Finds Declines in Cancer Incidence and Death in US, But Wide Variation in Lung Cancer Trends - (DGNews)
    TopAbstracts in Leukemias 11/26/2008 - (DGNews)
    TopAbstracts in Leukemias 11/19/2008 - (DGNews)
    TopAbstracts in Leukemias 11/12/2008 - (DGNews)
    TopAbstracts in Leukemias 11/05/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Leukaemias

    Webcasts/CME archive

     Recent cases - Leukaemias
      A Patient with Glycogen Storage Disease Type Ib Presenting with Acute Myeloid Leukemia (AML) Bearing Monosomy 7 and Translocation t(3;8)(q26;q24) after 14 Years of Treatment with Granulocyte Colony-Stimulating Factor (G-CSF): A Case Report
      Successful Outcome of Langerhans Cell Histiocytosis Complicated by Therapy-Related Myelodysplasia and Acute Myeloid Leukemia: A Case Report
      Hairy Cell Leukaemia Presenting with Ascites, Pleural Effusion and Increased CA 125 Serum Level
      Down Syndrome with Microgranular Variant of Acute Promyelocytic Leukemia in a Child: A Case Report
      Brucella Bacteremia in Patients with Acute Leukemia: A Case Series

      Cases archive
        




      my personal edition > leukaemias > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Dasatinib Controls Chronic Myelogenous Leukemia in Gleevec-Resistant Patients: Presented at AACR

      By Charlene Laino

      WASHINGTON, D.C. -- April 7, 2006 -- The second-generation tyrosine kinase inhibitor dasatinib (BMS-354825) shows promise for the treatment of patients with chronic myelogenous leukemia (CML) who have developed resistance to imatinib mesylate (Gleevec), suggest the results of several phase 2 studies.

      Charles Sawyers, MD, professor of medicine, Division of Hematology-Oncology, University of California in Los Angeles, United States, said there are now 5 phase 2 studies testing the agent in resistant patients.

      Imatinib is now considered front-line therapy for newly diagnosed CML. However, it is associated with a significant relapse rate, Dr. Sawyers explained.

      Several studies are currently evaluating dasatinib in the treatment of imatinib-resistant CML. Dr. Sawyers presented 6-month data on 4 of these studies on April 3rd at the 97th Annual Meeting of the American Association for Cancer Research (AACR).

      Among the findings:

      · In one study of 186 patients with chronic phase CML treated with dasatinib, 90 have had a complete hematologic remission, defined as normalization of blood counts. Additionally, 45 patients have had a major cytologic remission, defined as 35% or fewer Philadelphia chromosome positive cells.

      · In a study of 107 patients with accelerated phase CML, 59 had a complete hematologic remission and 31 have had a major cytologic remission.

      · In a study of 78 patients with lymphoid blast crisis, 35 had complete hematologic responses and 54 have had a major cytologic remission.

      · In a study of 74 patients with myeloid blast disease, 32 had a complete hematologic remission and 30 have had a major cytologic remission.

      In the phase 2 trial, 51% to 79% of patients developed Grade 3 and 4 myelosuppression, and 12% to 18% of patients have had pleural effusions.

      The fifth phase 2 study, a randomized trial pitting dasatinib against high-dose imatinib in patients with suboptimal responses to standard-dose imatinib, has just completed accrual, Dr. Sawyers said.


      [Presentation title: Development of the ABL Kinase Inhibitor Dasatinib (BMS-354825) in Imatinib-Resistant Philadelphia Chromosome Positive Leukemias. Abstract CP-2]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send